449 related articles for article (PubMed ID: 15345760)
1. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.
Citrome L; Jaffe A; Levine J; Allingham B; Robinson J
Psychiatr Serv; 2004 Sep; 55(9):1006-13. PubMed ID: 15345760
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
3. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
Østbye T; Curtis LH; Masselink LE; Hutchison S; Wright A; Dans PE; Schulman KA; Krishnan RR
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):407-15. PubMed ID: 15372671
[TBL] [Abstract][Full Text] [Related]
4. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.
Feldman PD; Hay LK; Deberdt W; Kennedy JS; Hutchins DS; Hay DP; Hardy TA; Hoffmann VP; Hornbuckle K; Breier A
J Am Med Dir Assoc; 2004; 5(1):38-46. PubMed ID: 14706127
[TBL] [Abstract][Full Text] [Related]
5. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
Ollendorf DA; Joyce AT; Rucker M
MedGenMed; 2004 Jan; 6(1):5. PubMed ID: 15208518
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature.
Cohen D
Pharmacopsychiatry; 2004 Jan; 37(1):1-11. PubMed ID: 14750042
[TBL] [Abstract][Full Text] [Related]
7. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.
Leslie DL; Rosenheck RA
Am J Psychiatry; 2004 Sep; 161(9):1709-11. PubMed ID: 15337666
[TBL] [Abstract][Full Text] [Related]
8. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
[TBL] [Abstract][Full Text] [Related]
9. Comparative safety of antipsychotics: another look at the risk of diabetes.
Moisan J; Turgeon M; Desjardins O; Grégoire JP
Can J Psychiatry; 2013 Apr; 58(4):218-24. PubMed ID: 23547645
[TBL] [Abstract][Full Text] [Related]
10. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population.
Miller EA; Leslie DL; Rosenheck RA
J Nerv Ment Dis; 2005 Jun; 193(6):387-95. PubMed ID: 15920379
[TBL] [Abstract][Full Text] [Related]
11. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
Byerly MJ; Nakonezny PA; Bettcher BM; Carmody T; Fisher R; Rush AJ
Schizophr Res; 2006 Sep; 86(1-3):244-50. PubMed ID: 16730951
[TBL] [Abstract][Full Text] [Related]
12. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.
Kuo CJ; Yang SY; Liao YT; Chen WJ; Lee WC; Shau WY; Chang YT; Tsai SY; Chen CC
Schizophr Bull; 2013 May; 39(3):648-57. PubMed ID: 22282455
[TBL] [Abstract][Full Text] [Related]
13. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone.
Manu P; Correll CU; Wampers M; van Winkel R; Yu W; Shiffeldrim D; Kane JM; De Hert M
Schizophr Res; 2013 Feb; 143(2-3):358-62. PubMed ID: 23231880
[TBL] [Abstract][Full Text] [Related]
14. [Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].
Rubio G; Gómez-de-la-Cámara A; Ledesma F; Burón JA; Rodríguez-Morales A; Martínez-Junquera G;
Med Clin (Barc); 2006 Apr; 126(12):441-4. PubMed ID: 16620729
[TBL] [Abstract][Full Text] [Related]
15. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.
Lambert BL; Cunningham FE; Miller DR; Dalack GW; Hur K
Am J Epidemiol; 2006 Oct; 164(7):672-81. PubMed ID: 16943266
[TBL] [Abstract][Full Text] [Related]
16. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
Moisan J; Grégoire JP
Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
Karagianis J; Williams R; Davis L; Procyshyn R; Monga N; Hanley J; Chandrasena R; Thakur A; Dickson R
Curr Med Res Opin; 2009 Sep; 25(9):2121-32. PubMed ID: 19601707
[TBL] [Abstract][Full Text] [Related]
18. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine.
Sumiyoshi T; Roy A; Anil AE; Jayathilake K; Ertugrul A; Meltzer HY
J Clin Psychopharmacol; 2004 Jun; 24(3):345-8. PubMed ID: 15118492
[No Abstract] [Full Text] [Related]
19. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
Scheltema Beduin AA; Swets M; Machielsen M; Korver N;
J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156
[TBL] [Abstract][Full Text] [Related]
20. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
